Dry powder versus intravenous and nebulized gentamicin in cystic fibrosis and bronchiectasis: A pilot study

American Journal of Respiratory and Critical Care Medicine

Volumn 160, Issue 5 I, 1999, Pages 1711-1716

  Crowther Labiris, N Renée ^c   Holbrook, Anne M ^d   Chrystyn, Henry ^d   Macleod, Stuart M ^d   Newhouse, Michael T ^a,b  

^a NEKTAR THERAPEUTICS   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CENTRE FOR EVALUATION OF MEDICINES   (Canada)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

GENTAMICIN;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BRONCHIECTASIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; CYSTIC FIBROSIS; DRY POWDER; FEMALE; GRAM NEGATIVE INFECTION; HUMAN; INHALATIONAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; MINIMUM INHIBITORY CONCENTRATION; NEBULIZATION; PILOT STUDY; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RANDOMIZED CONTROLLED TRIAL;

EID: 0345534831     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/ajrccm.160.5.9810080     Document Type: Article

References (42)

1. Truchsis, M., and M. N. Swartz. 1991. Bronchiectasis: a current view. Curr. Clin. Top. Infect. Dis. 11:170-205.
2. Nicotra, M. B. 1994. Bronchiectasis. Semin. Respir. Infect. 9:31-40.
3. Ramsey, B. W., H. L. Dorkin, J. D. Eisenberg, R. L. Gibson, I. R. Harwood, R. M. Kravitz, D. V. Schidlow, R. W. Wilmott, S. J. Astley, M. A. McBurnie, K. Wentz, and A. L. Smith. 1993. Efficacy of aerosolized tobramycin in patients with cystic fibrosis. N. Engl. J. Med. 328: 1740-1746.
4. Horrevorts, A. M., O. M. J. Driessen, M. F. Michel, and K. F. Kerrebijn. 1988. Pharmacokinetics of antimicrobial drugs in cystic fibrosis. Aminoglycoside antibiotics. Chest 94(Suppl. 2): 120s-125s.
5. Kulczycki, L. L., T. M. Murphy, and J. A. Bellanti. 1978. Pseudomonas colonization in cystic fibrosis: a study of 160 patients. J.A.M.A. 240: 30-34.
6. Rubio, T. T. 1986. Infection in patients with cystic fibrosis. Am. J. Med. 81(Suppl. 1A):73-77.
7. van Klingeren, B. 1988. Antibiotic resistance in Pseudomonas aeruginosa, Hemophilus influenzae and Staphylococcus. Chest 94(Suppl. 2): 103s-109s.
8. Mukhopadhyay, S., M. Singh, J. I. Cater, S. Ogston, M. Franklin, and R. E. Olver. 1996. Nebulized antipseudomonal antibiotic therapy in cystic fibrosis: a meta-analysis of benefits and risks. Thorax 51:364-368.
9. Rumsey, B. W., M. S. Pepe, J. M. Quan, K. I., Otto, A. Montgomery, J. Williams-Warren, K. M. Vasiljev, D. Borowitz, C. M. Bowman, B. C. Marshall, S. Marshall, and A. L. Smith. 1999. Intermittent administration of inhaled tobramyein in patients with cystic fibrosis. N. Engl. J. Med. 340:23-30.
10. Boat, T. F. 1988. Cystic fibrosis. In J. F. Murray and J. A. Nadel, editors. Textbook of Respiratory Medicine. W.B. Saunders, Philadelphia. 1126-1152.
11. Kepron, W. 1996. Cystic fibrosis in the young adult. Medicine North America. March:28-32.
12. Hoiby, N., B. Friis, K. Jensen, C. Koch, N. E. Moller, S. Stovring, and M. Szaff. 1982. Antimicrobial chemotherapy in cystic fibrosis patients. Acta. Paediatr. Suppl. 301:75-100.
13. Chan, G. L. C. 1989. Alternative dosing strategy for aminoglycosides: impact on efficacy, nephrotoxicity, and ototoxicity. Drug Intell. Clin. Pharm. 23:788-793.
14. Moore, R. D., P. S. Lietman, and C. R. Smith. 1987. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J. Infect. Dis. 155:93-99.
15. Barclay, M. L., and E. J. Begg. 1994. Aminoglycoside toxicity and relation to dose regimen. Adverse Drug React. Toxicol. Rev. 13:207-234.
16. Hodson, M. E., A. R. L. Penketh, and J. C. Batten. 1981. Aerosol carbenicillin and gentamicin treatment of Pseudomonas aeruginosa infection in patients with cystic fibrosis. Lancet November 21:1137-1139.
17. Penketh, A. R. L. 1982. Long-term use of aerosol antibiotics in adults with cystic fibrosis. In Proceedings of the 11th Annual Meeting of the European Working Group in Cystic Fibrosis. Belgian Cystic Fibrosis Association, Brussels, Belgium.
18. Wall, M. A., A. B. Terry, J. Eisenherg, M. McNamara, and R. Cohen. 1983. Inhaled antibiotics in cystic fibrosis. Lancet 1(8337):1325.
19. Littlewood, J. M., M. G. Miller, A. T. Ghoneim, and C. H. Ramsden. 1985. Nebulized colomycin for early Pseudomonas colonization in cystic fibrosis. Lancet 1(8433):865.
20. Stead, R. J., M. E. Hodson, and J. C. Batten. 1987. Inhaled ceflazidime compared with gentamicin and carbenicillin in older patients with cystic fibrosis infected with Pseudomonas aeruginosa. Br. J. Dis. Chest 81: 272-278.
21. Eisenberg, J., M. Pepe, J. Williams-Warren, M. Vasiliev, A. B. Montgomery, A. L. Smith, B. W. Ramsey, and the Aerosolized Tobramycin Study Group. 1997. A comparison of peak sputum lobramyein concentration in patients with cystic fibrosis using jet and ultrasonic nebulizer systems. Cheat 111:955-962.
22. Newman, S. P., A. R. Clark, N. Talaee, and S. W. Clarke. 1991. Lung deposition of 5mg Intal from a pressurized metered dose inhaler assessed by radiotracer technique. Int. J. Pharmaceutics 74;203-208.
23. Irani, F. A., N. L. Jones, M. Gent, and M. T. Newhouse. 1972. Evaluation of disodium cromoglycate in intrinsic and extrinsic asthma. Am. Rev. Respir. Dis. 106:179-185.
24. Apparatus A. British Pharmacopoeia 1993, Appendix XVII. 1998. Her Majesty's Stationery Office, London.
25. Nantel, N. P., M. T. Newhouse, and M. R. Sears. 1996. Pediatric inspiratory flows through a novel multi-dose DPI (Clickhaler ™) in pediatric patients with asthma. In R. N. Dalby, P. R. Byran, and S. T. Farr, editors. Respiratory Drug Delivery, 5th ed. InterPharm Inc., Buffalo Grove, IL. 386-388.
26. Nantel, N. P., J. C. Smerck, and M. T. Newhouse. 1995. Flow target system for DPI clinical trials (abstract). J. Aerosol Med. 8:A103.
27. Newhouse, M. T. 1998. The current laboratory determination of "respirable mass" is not clinically relevant. J. Aerosol Med. 11 (Suppl.):S122-S132.
28. Bosso, J. A., M. V. Relling, P. L. Townsend, and L. M. Strand. 1987. Intrapatient variation in aminoglycoside disposition in cystic fibrosis. Clin. Pharm. 6:54-58.
29. Morin, S., J. Tetrault, L. James, J. E. Hoppe-Bauer, and M. Pezzlo. 1994. Specimen acceptability: evaluation of specimen quality. In H. D. Isenberg, editor. Clinical Microbiology Procedures Handbook. American Society of Microbiology, Washington, DC.
30. Wong, K., M. C. Roberts, L. Owens, M. Fife, and A. L. Smith. 1984. Selective media for the quantitation of bacteria in cystic fibrosis sputum. J. Med. Microbial. 17:113-119.
31. Boe, J., O. Stiksa, K. Svensson, and E. Asbrink. 1992. New method of evaluating patient preference for different inhalation delivery systems. Ann. Allergy 68:255-260.
32. Kleinbaum, D. G., L. I. Kupper, and K. E. Miller. 1988. Applied Regression Analysis and Other Multivariable Methods, 2nd ed. Wadsworth Publishing Company, Belmont, CA.
33. Norman, G. R. and D. L. Sireiner. 1994. Biostatistics: The Bare Essentials. Mosby-Year Book Inc., Toronto.
34. Lourenco, R. V., R. Loddenkemper, and R. W. Carton. 1972. Patterns of distribution and clearance of aerosols in patients with bronchiectasis. Am. Rev. Respir. Dis. 106:857-866.
35. Touw, D. J., R. W. Brimicombe, M. E. Hodson, H. G. M. Heijerman, and W. Bakker. 1995. Inhalation of antibiotics in cystic fibrosis. Eur. Respir. J. 8:1594-1604.
36. Ryrfeldt, A. 1990. The bronchial circulation - a significant local distribution system in the lung, in inhalation therapy? J. Aerosol. Med. 3:165-168.
37. Deffebach, M. E., N. B. Charan, S. Lakshminarayan, and J. Butler. 1987. The bronchial circulation. Am. Rev. Respir. Dis. 135:463-481.
38. Goldman, J. M., S. M. Bayston, S. O'Connor, and R. F., Meigh. 1990. Inhaled micronised gentamicin powder: a new delivery system. Thorax 45:939-940.
39. Conway, S. P., A. Watson, M. N. Pond, S. Bayston, R. Booth, and A. Ghonheim. 1993. Sputum gentamicin levels after delivery by rotahaler and nebulizer. Pediatr. Pulmonol. 9(Suppl.):250.
40. Mendelman, P. M., A. L. Smith, J. Levy, A. Weber, B. Ramsey, and R. L. Davis. 1985. Aminoglycoside penetration, inactivation, and efficacy in cystic fibrosis sputum. Am. Rev. Respir. Dis. 132:761-765.
41. Levy, J., A. L. Smith, M. A. Kenny, B. Ramsey, and F. D. Schoenknecht. 1983. Bioactivity of gentamicin in purulent sputum from patients with cystic fibrosis or bronchiectasis: comparison with activity in serum. J. Infect. Dis. 148:1069-1076.
42. Bryant, R. E. and D. Hammond. 1974. Interaction of purulent material with antibiotics used to treat Pseudomonas infections. Antimicrob. Agents Chemother. 6:702-707.